Best Supplements for Menopause & Perimenopause, Ranked
Not medical advice. This ranks twelve supplements sold for menopause and perimenopause by their randomized trials and reads the labels sold for menopause in the NIH database. Hormone therapy is the treatment doctors prescribe for hot flashes and is outside this page’s scope.
Quick answer
Two supplements hold up in postmenopausal trials, calcium with vitamin D for bone and creatine for muscle, and neither is sold as a menopause product. For hot flashes, soy isoflavones and vitamin E each trim roughly one flash a day in low-quality trials; black cohosh, red clover, dong quai and omega-3 tested no better than placebo; chasteberry has no menopause trial. Black cohosh is still on 75.2% of the 161 menopause labels we read.
Buy by symptom, not by the word on the bottle. Bone: 1,200 mg calcium a day from all sources and 600–800 IU vitamin D, $0.24 a day to fill a food gap. Muscle: 5 g creatine with lifting, $0.27 a day. Flashes: nothing here does what a prescription does. See all twelve ranked →
On this page
Twelve supplements sold for menopause, ranked by their trials
Product links go to Amazon and we may earn a commission if you buy. It never changes which product we pick or what we say about it. How we choose.
Ordered by the size and quality of the randomized trials in menopausal, perimenopausal or postmenopausal women. Cost is the current Amazon price for the exact pack divided into the dose the cited trial used; rows without a product say so. Label share is from our census of 161 menopause labels, printed only where it held in both halves.
| # | Ingredient | Evidence | What the trials found | Studied dose | On menopause labels | Our pick, cost/day at dose |
|---|---|---|---|---|---|---|
| 1 | Calcium + vitamin D | Trial-supported | Denser hips in 36,282 women; hip fractures not significantly fewer. | 1,200 mg calcium/day, all sources; 600–800 IU D | 21.1% |  Solgar Calcium Citrate with Vitamin D3 $0.17 two tablets (500 mg) plus one 2,000 IU softgel |
| 2 | Creatine monohydrate | Trial-supported | Lean mass +0.37 kg, leg press +7.5 kg across 7 trials, with lifting; bone unchanged. | 5 g a day with resistance training | not a held figure |  Optimum Nutrition Micronized Creatine Monohydrate $0.27 |
| 3 | Soy isoflavones | Mixed | 0.79 fewer hot flashes a day; 74% of trials at high risk of bias. | Varied by trial; not standardised | not a held figure | not carried; no trial dose to price |
| 4 | Vitamin E | Mixed | One fewer flash a day than placebo in 105 women; called marginal by its authors. | 400–800 IU a day | 25.5% |  Nature Made Vitamin E 180 mg $0.08 |
| 5 | Magnesium | Mixed | No effect on flashes in 289 women; sleep onset 17 minutes faster in 151 older adults. | 500 mg in the sleep trial; 200–350 mg in practice | not a held figure |  Nature Made Magnesium Glycinate 200mg $0.19 one 200 mg capsule |
| 6 | Collagen peptides | One trial | Spine and hip density rose against placebo in 131 women over a year. | 5 g a day | not a held figure |  Sports Research Collagen Peptides $0.37 5 g of an 11 g scoop |
| 7 | Ashwagandha | One trial | Menopause Rating Scale fell more than placebo in 100 perimenopausal women; liver caveat. | 300 mg root extract twice a day | 7.5% |  Nootropics Depot KSM-66 Ashwagandha $0.51 two capsules |
| 8 | Black cohosh | Trials found nothing | 16 trials, 2,027 women: 0.07 flushes a day versus placebo. | 40 mg a day (trial median) | 75.2% | not carried; no trial dose to price |
| 9 | Red clover | Trials found nothing | 57% fewer symptoms at 12 months against 63% on placebo. | No effective dose established | 22.4% | not carried; no trial dose to price |
| 10 | Omega-3 | Trials found nothing | 2.5 fewer flashes a day on omega-3, 2.7 on placebo, in 355 women. | 1.8 g a day | not a held figure |  Sports Research Triple Strength Omega-3 $0.65 two softgels; not for flashes |
| 11 | Dong quai | Trials found nothing | No difference from placebo in 71 women over 24 weeks. | No effective dose established | 35.4% | not carried; no trial dose to price |
| 12 | Chasteberry (vitex) | No menopause trial | 12 randomized trials, all in PMS, PMDD or prolactin disorders. | No menopause dose established | 47.8% | not carried; no trial dose to price |
The 5 rows without a product (soy isoflavones, black cohosh, red clover, dong quai, chasteberry (vitex)) are the ingredients that fill the menopause shelf: two have Cochrane- or JAMA-level reviews finding nothing, one has a single trial finding nothing, and one has never been tested in menopause.
Bone: calcium and vitamin D fill a gap; they are not a fracture drug
The largest trial is the Women’s Health Initiative calcium and vitamin D arm: 36,282 postmenopausal women randomized to 1,000 mg of calcium carbonate plus 400 IU of vitamin D3 a day or placebo for an average of 7 years. Hip bone density ended 1.06% higher, the hazard ratio for hip fracture was 0.88 with an interval that crossed one, and kidney stones were more common (hazard ratio 1.17) (Jackson 2006, PMID 16481635). Across 26 randomized trials pooled in 2015, calcium supplements cut total fractures by about a tenth (relative risk 0.89) and hip fractures not at all (0.95), with funnel-plot evidence of publication bias (Bolland 2015, PMID 26420387). The US Preventive Services Task Force reads the same trials as adequate evidence that 400 IU or less of vitamin D with 1,000 mg or less of calcium does not prevent fractures in postmenopausal women living independently (USPSTF 2018, PMID 29677309).
It still tops this ranking because it is the only row with tens of thousands of women in placebo-controlled trials and a measurable effect on bone. The practical reading, from the calcium for seniors guide: the target is 1,200 mg a day from food and supplements together, so the pill covers the gap after dairy and greens, with the 600–800 IU vitamin D RDA beside it. The one collagen trial belongs here too: 131 postmenopausal women took 5 g of specific collagen peptides or placebo for a year and the spine T-score moved +0.1 on collagen against -0.03 on placebo (König 2018, PMID 29337906); a single trial with a surrogate endpoint, which is why it ranks sixth.
Muscle: creatine works after menopause, but only with the lifting
Creatine is the one supplement with a meta-analysis specifically in postmenopausal women: 7 randomized placebo-controlled trials, 608 women, mean age about 62, with lean mass +0.37 kg and leg-press strength +7.5 kg on creatine, and the benefit appearing when 5 g a day or more was combined with resistance training (Naddafha 2026, PMID 42141930). Bone is the caveat. In a 2-year trial of 237 postmenopausal women on a lifting and walking programme, creatine did not change bone density at the hip or spine, though it preserved two geometric measures of femoral-neck strength and shaved walking time (Chilibeck 2023, PMID 37144634); at 3 g a day without a training programme, 200 women with osteopenia gained nothing in bone, lean mass or function over two years (Sales 2020, PMID 31257405). The creatine for women guide covers loading, water weight and the brain trials.
Hot flashes: the shelf’s lead ingredients tested no better than placebo
Black cohosh is the ingredient the shelf is built on, and the Cochrane review is unambiguous: 16 randomized trials, 2,027 women, a median dose of 40 mg a day for a mean 23 weeks, and a difference from placebo of 0.07 hot flushes a day, with menopausal symptom scores no different either (Leach 2012, PMID 22972105). The 12-month four-arm trial makes the point in one picture: vasomotor symptoms fell 34% on black cohosh, 57% on red clover, 63% on placebo and 94% on estrogen plus progestin, and only the hormone arm differed from placebo (Geller 2009, PMID 19609225). Dong quai alone, in 71 postmenopausal women for 24 weeks, produced no estrogen-like change and no difference in flushes or the Kupperman index (Hirata 1997, PMID 9418683). Omega-3 at 1.8 g a day for 12 weeks cut flashes by 2.5 a day in 355 women, and placebo cut them by 2.7, with sleep and mood unchanged (Cohen 2014, PMID 23982113).
The two with a signal are modest. Soy isoflavones: the JAMA meta-analysis of 62 trials in 6,653 women found phytoestrogens associated with 1.31 fewer hot flashes a day and soy isoflavones with 0.79 fewer, no change in night sweats, 74% of trials at high risk of bias; Chinese herbal formulas showed no association (Franco 2016, PMID 27327802). Vitamin E: 51 women went from 5 flashes a day on placebo to 3.19 on 400 IU (Ziaei 2007, PMID 17664882), and in a randomized crossover of 105 breast-cancer survivors, 800 IU gave one fewer hot flash a day than placebo, which the authors called marginal (Barton 1998, PMID 9469333). The 2023 North American Menopause Society position statement lists dietary supplements, herbal remedies and soy foods and extracts as not recommended for vasomotor symptoms, and names cognitive-behavioral therapy, hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant as the non-hormonal options that work (NAMS 2023, PMID 37252752). Hormone therapy remains the most effective treatment for women who can take it; it is the treatment doctors prescribe and outside this page’s scope.
Sleep: magnesium, modestly, and not for night sweats
Magnesium is the one row where the hot-flash trial and the sleep trials point different ways. The placebo-controlled trial of 289 postmenopausal women found magnesium oxide no better than placebo for hot-flash frequency or score, only more diarrhea (Park 2015, PMID 25423327). For sleep, a meta-analysis of 3 trials in 151 older adults found sleep onset 17.4 minutes faster on magnesium, at 500 mg in the largest trial, with low-quality evidence and no menopausal cohort (Mah 2021, PMID 33865376). The magnesium for menopause page walks both; the short version is 200 to 350 mg of glycinate for sleep, and nothing for flashes.
Perimenopause: one ashwagandha trial, and chasteberry has none
Ashwagandha has exactly one trial in the right women: 100 perimenopausal women with climacteric symptoms, 300 mg of a root extract twice a day or placebo for 8 weeks, with the Menopause Rating Scale and the menopause quality-of-life score improving more than placebo, alongside a rise in estradiol and a fall in FSH (Gopal 2021, PMID 34553463). A real result and a single one, and ashwagandha carries a published liver-injury case series (liver safety page), so it earns “one trial” and no more. Chasteberry is the opposite case: 12 randomized trials in the systematic review, eight in PMS, two in PMDD and two in latent hyperprolactinaemia, and none in menopause or perimenopause (van Die 2013, PMID 23136064). It is on 47.8% of menopause labels on the strength of a PMS literature.
We read 161 labels sold for menopause: a black cohosh shelf
Original researchEvery on-market label the NIH Dietary Supplement Label Database returned for “menopause” on 2026-09-18, read in full; the 161 whose product name or target group names menopause, perimenopause or hot flashes, from 97 brands, are the population (600 labels that merely mention the word were excluded).
75.2% contain black cohosh, 47.8% chasteberry, 35.4% dong quai, 22.4% red clover and 11.2% sage. Of the supported pair, calcium is on 21.1% of labels and vitamin D on 12.4%; vitamin E is on 25.5%, ashwagandha on 7.5%, and DHEA, whose 23-trial meta-analysis found no effect on sexual function after menopause (Elraiyah 2014, PMID 25279571), on 0%. The median label lists 13 ingredients and only 2.5% are a single active ingredient. Creatine does not appear at all. The shelf is organised around the ingredients that failed their trials; the ones that passed are sold in other aisles.
| Item | Value (%) |
|---|---|
| Black cohosh | 75.2% |
| Chasteberry (vitex) | 47.8% |
| Dong quai | 35.4% |
| Vitamin E | 25.5% |
| Red clover | 22.4% |
| Calcium | 21.1% |
| Vitamin D | 12.4% |
| Ashwagandha | 7.5% |
How we read the labels, and what did not hold
Method: 761 on-market labels from the NIH Dietary Supplement Label Database ranked search for “menopause”, read in full on 2026-09-18; 161 sold for menopause analysed. Ingredient presence is read from each hit’s ingredient list; mineral and vitamin rows are matched by category, so magnesium stearate and calcium phosphate excipients do not count. Every figure was recomputed in two halves of the corpus split by label-id parity: 15 of 19 checks agreed within tolerance and only those are printed. Not printed (4): share containing soy isoflavones; share containing magnesium; share with a blend; share with no vitamin or mineral row. Cost per day is the current Amazon price divided by servings, times the servings the studied dose needs; the table states the multiplier where it is not one. What it cannot tell you: how much of a proprietary blend is any one botanical, whether a product contains what its label says, or which of these you personally need.
What to buy, if the trials are the guide
Vitamin E at 400 IU (Nature Made Vitamin E 180 mg, $0.08 a day, USP Verified) is the cheapest thing here to try for flashes; expect about one fewer a day. Ashwagandha (Nootropics Depot KSM-66 Ashwagandha, $0.51 a day at 300 mg twice daily) is the one-trial perimenopause option, with the liver caveat. We do not carry black cohosh, red clover, dong quai or chasteberry, and this page is the reason.
Frequently asked questions
What is the best supplement for menopause?
None treats hot flashes the way the prescription options do, and the two with the most trial support are not sold as menopause products. Calcium with vitamin D, at 1,200 mg of calcium a day from all sources, gave 36,282 postmenopausal women slightly denser hips over 7 years without significantly fewer hip fractures. Creatine at 5 g a day with resistance training added about 0.37 kg of lean mass across 7 trials. For flashes, soy isoflavones and vitamin E each trim roughly one a day in low-quality trials; the rest tested no better than placebo.
Does black cohosh work for hot flashes?
Not in the randomized trials. The Cochrane review pooled 16 trials in 2,027 women at a median 40 mg a day and found 0.07 hot flushes a day difference from placebo. In a 12-month four-arm trial, vasomotor symptoms fell 34% on black cohosh, 63% on placebo and 94% on estrogen plus progestin; only the hormone arm beat placebo. It is still on 75.2% of the 161 menopause labels we read.
What helps perimenopause symptoms naturally?
The list is short. One 8-week trial of 100 perimenopausal women found 300 mg of ashwagandha root extract twice a day lowered the Menopause Rating Scale more than placebo; it is a single trial, and ashwagandha has a published liver-injury case series. Chasteberry has 12 randomized trials in its systematic review and none is in menopause or perimenopause. For sleep, magnesium: about 17 minutes faster sleep onset in older adults, at low quality.
Do soy isoflavones reduce hot flashes?
Modestly, in trials the reviewers did not trust much. Across 62 trials in 6,653 women, phytoestrogens were associated with 1.31 fewer hot flashes a day and soy isoflavones with 0.79 fewer, no change in night sweats, and 74% of trials were at high risk of bias. The 2023 North American Menopause Society statement lists soy foods and extracts as not recommended for vasomotor symptoms. We do not carry a soy isoflavone product.
How much does an evidence-based menopause stack cost per day?
Two tablets of Solgar Calcium Citrate with Vitamin D3 for a 500 mg gap plus one Nature Made Vitamin D3 2000 IU softgel comes to $0.24 a day at current Amazon prices. Adding 5 g of Optimum Nutrition Micronized Creatine Monohydrate is $0.27 more, which only pays off if you lift. Under $0.60 a day for the two supported rows, less than most menopause blends whose lead ingredient tested no better than placebo.
Related guides
- Magnesium for menopause: what the trials found
- Calcium for seniors and postmenopausal bone
- Creatine for women: menstruation to menopause
- Collagen for women: skin, bone and the one trial
- Vitamin D for women: pregnancy to menopause
- Supplements for women, ranked by evidence
- Ashwagandha and the liver
- Can't sleep: what the evidence supports
Sources
- Leach MJ, Moore V. “Black cohosh (Cimicifuga spp.) for menopausal symptoms.” Cochrane Database Syst Rev. 2012. PMID: 22972105
- Geller SE, et al. “Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.” Menopause. 2009. PMID: 19609225
- Franco OH, et al. “Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.” JAMA. 2016. PMID: 27327802
- Cohen LS, et al. “Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.” Menopause. 2014. PMID: 23982113
- Ziaei S, et al. “The effect of vitamin E on hot flashes in menopausal women.” Gynecol Obstet Invest. 2007. PMID: 17664882
- Barton DL, et al. “Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.” J Clin Oncol. 1998. PMID: 9469333
- Hirata JD, et al. “Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial.” Fertil Steril. 1997. PMID: 9418683
- van Die MD, et al. “Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.” Planta Med. 2013. PMID: 23136064
- Gopal S, et al. “Effect of an ashwagandha (Withania Somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study.” J Obstet Gynaecol Res. 2021. PMID: 34553463
- Park H, et al. “North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.” Menopause. 2015. PMID: 25423327
- Mah J, Pitre T. “Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis.” BMC Complement Med Ther. 2021. PMID: 33865376
- Jackson RD, et al. “Calcium plus vitamin D supplementation and the risk of fractures.” N Engl J Med. 2006. PMID: 16481635
- Bolland MJ, et al. “Calcium intake and risk of fracture: systematic review.” BMJ. 2015. PMID: 26420387
- US Preventive Services Task Force (Grossman DC, et al). “Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: US Preventive Services Task Force Recommendation Statement.” JAMA. 2018. PMID: 29677309
- Naddafha S, et al. “Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis.” J Int Soc Sports Nutr. 2026. PMID: 42141930
- Chilibeck PD, et al. “A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health.” Med Sci Sports Exerc. 2023. PMID: 37144634
- Sales LP, et al. “Creatine Supplementation (3 g/d) and Bone Health in Older Women: A 2-Year, Randomized, Placebo-Controlled Trial.” J Gerontol A Biol Sci Med Sci. 2020. PMID: 31257405
- König D, et al. “Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women: A Randomized Controlled Study.” Nutrients. 2018. PMID: 29337906
- Elraiyah T, et al. “The benefits and harms of systemic DHEA in postmenopausal women with normal adrenal function: a systematic review and meta-analysis.” J Clin Endocrinol Metab. 2014. PMID: 25279571
- The North American Menopause Society. “The 2023 nonhormone therapy position statement of The North American Menopause Society.” Menopause. 2023. PMID: 37252752
- NIH Office of Dietary Supplements. Calcium and Vitamin D fact sheets for health professionals. ods.od.nih.gov
- NIH Office of Dietary Supplements. Dietary Supplement Label Database. dsld.od.nih.gov (labels read in full 2026-09-18).